{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:24:35Z","timestamp":1789698275501,"version":"4.0.1"},"reference-count":123,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Endocr Metab"],"published-print":{"date-parts":[[2017]]},"DOI":"10.4103\/2230-8210.196016","type":"journal-article","created":{"date-parts":[[2016,12,21]],"date-time":"2016-12-21T06:39:43Z","timestamp":1482302383000},"page":"196","source":"Crossref","is-referenced-by-count":11,"title":["A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus"],"prefix":"10.4103","volume":"21","author":[{"given":"Nishant","family":"Garodia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KM","family":"Prasanna Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujoy","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Canovatchel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujith","family":"Rajashekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/2230-8210.196016-1","unstructured":"International Diabetes Federation. IDF Diabetes Atlas. 7th ed. Brussels, Belgium: International Diabetes Federation; 2015. Available from: http:\/\/www.diabetesatlas.org\/resources\/2015-atlas.html. [Last accessed on 2016 Jul 15]."},{"key":"key-10.4103\/2230-8210.196016-2","first-page":"110","volume-title":"Trends in prevalence of diabetes in Asian countries","author":"Ramachandran","year":"2012","journal-title":"World J Diabetes"},{"key":"key-10.4103\/2230-8210.196016-3","first-page":"370","volume-title":"Current status of management, control, complications and psychosocial aspects of patients with diabetes in India: Results from the DiabCare India 2011 Study","author":"Mohan","year":"2014","journal-title":"Indian J Endocrinol Metab"},{"key":"key-10.4103\/2230-8210.196016-4","first-page":"37","volume-title":"Obesity in India: The weight of the nation","author":"Kalra","year":"2012","journal-title":"J Med Nutr Nutraceuticals"},{"key":"key-10.4103\/2230-8210.196016-5","first-page":"139","volume-title":"Prevalence of generalized and abdominal obesity in urban and rural India \u2013 the ICMR-INDIAB Study (Phase-I) [ICMR- NDIAB-3]","author":"Pradeepa","year":"2015","journal-title":"Indian J Med Res","ISSN":"https:\/\/id.crossref.org\/issn\/0971-5916","issn-type":"print"},{"key":"key-10.4103\/2230-8210.196016-6","first-page":"1265","volume-title":"Regional variation in the prevalence of overweight\/obesity, hypertension and diabetes and their correlates among the adult rural population in India","author":"Meshram","year":"2016","journal-title":"Br J Nutr"},{"key":"key-10.4103\/2230-8210.196016-7","first-page":"3022","volume-title":"Prevalence of diabetes and prediabetes (impaired fasting glucose and\/or impaired glucose tolerance) in urban and rural India: Phase I results of the Indian Council of Medical Research-INdia DIABetes (ICMR-INDIAB) study","author":"Anjana","year":"2011","journal-title":"Diabetologia"},{"key":"key-10.4103\/2230-8210.196016-8","first-page":"21","volume-title":"Factors associated with glucose tolerance, pre-diabetes, and type 2 diabetes in a rural community of South India: A cross-sectional study","author":"Little","year":"2016","journal-title":"Diabetol Metab Syndr"},{"key":"key-10.4103\/2230-8210.196016-9","first-page":"1547","volume-title":"The target of metformin in type 2 diabetes","author":"Ferrannini","year":"2014","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2230-8210.196016-10","first-page":"1106","volume-title":"Thiazolidinediones","author":"Yki-J\u00e4rvinen","year":"2004","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2230-8210.196016-11","first-page":"737","volume-title":"Sulfonylureas in NIDDM","author":"Groop","year":"1992","journal-title":"Diabetes Care"},{"key":"key-10.4103\/2230-8210.196016-12","first-page":"194","volume-title":"Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis","author":"Amori","year":"2007","journal-title":"JAMA"},{"key":"key-10.4103\/2230-8210.196016-13","first-page":"S253","volume-title":"Insulin therapy for type 2 diabetes","author":"Swinnen","year":"2009","journal-title":"Diabetes Care"},{"key":"key-10.4103\/2230-8210.196016-14","first-page":"685","volume-title":"Early insulin therapy and the risk of cardiovascular disease in Type 2 diabetes","author":"Nicasio","year":"2005","journal-title":"Therapy"},{"key":"key-10.4103\/2230-8210.196016-15","first-page":"995","volume-title":"Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes","author":"Cook","year":"2005","journal-title":"Diabetes Care"},{"key":"key-10.4103\/2230-8210.196016-16","first-page":"457","volume-title":"Secondary failure of glycemic control for patients adding thiazolidinedione or sulfonylurea therapy to a metformin regimen","author":"Riedel","year":"2007","journal-title":"Am J Manag Care"},{"key":"key-10.4103\/2230-8210.196016-17","first-page":"1102","volume-title":"Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy","author":"Riedel","year":"2007","journal-title":"Pharmacotherapy"},{"key":"key-10.4103\/2230-8210.196016-18","first-page":"1335","volume-title":"More patients get good diabetes control, but only a minority meet all goals","author":"Mitka","year":"2013","journal-title":"JAMA"},{"key":"key-10.4103\/2230-8210.196016-19","first-page":"466","volume-title":"Relationship of oral antihyperglycemic (sulfonylurea or metformin) medication adherence and hemoglobin HbA1c goal attainment for HMO patients enrolled in a diabetes disease management program","author":"Lawrence","year":"2006","journal-title":"J Manag Care Pharm"},{"key":"key-10.4103\/2230-8210.196016-20","first-page":"314","volume-title":"Patient adherence to medication requirements for therapy of type 2 diabetes","author":"Bailey","year":"2011","journal-title":"Int J Clin Pract"},{"key":"key-10.4103\/2230-8210.196016-21","first-page":"457","volume-title":"Poor achievement of guidelines-recommended targets in type 2 diabetes: Findings from a contemporary prospective cohort study","author":"Braga","year":"2012","journal-title":"Int J Clin Pract"},{"key":"key-10.4103\/2230-8210.196016-22","first-page":"S264","volume-title":"Therapy in the early stage: Incretins","author":"Cernea","year":"2011","journal-title":"Diabetes Care"},{"key":"key-10.4103\/2230-8210.196016-23","first-page":"2427","volume-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","author":"Kahn","year":"2006","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2230-8210.196016-24","first-page":"131","volume-title":"Diabetes treatment, part 2: Oral agents for glycemic management","author":"Fowler","year":"2007","journal-title":"Clin Diabetes"},{"key":"key-10.4103\/2230-8210.196016-25","first-page":"S18","volume-title":"When oral agents fail: Practical barriers to starting insulin","author":"Korytkowski","year":"2002","journal-title":"Int J Obes Relat Metab Disord"},{"key":"key-10.4103\/2230-8210.196016-26","first-page":"220","volume-title":"Transition to insulin in type 2 diabetes: Family physicians' misconception of patients' fears contributes to existing barriers","author":"Nakar","year":"2007","journal-title":"J Diabetes Complications"},{"key":"key-10.4103\/2230-8210.196016-27","first-page":"1335","volume-title":"Update on developments with SGLT2 inhibitors in the management of type 2 diabetes","author":"Nauck","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"key-10.4103\/2230-8210.196016-28","first-page":"733","volume-title":"Biology of human sodium glucose transporters","author":"Wright","year":"2011","journal-title":"Physiol Rev"},{"key":"key-10.4103\/2230-8210.196016-29","first-page":"438","volume-title":"AACE\/ACE comprehensive diabetes management algorithm 2015","author":"Garber","year":"2015","journal-title":"Endocr Pract"},{"key":"key-10.4103\/2230-8210.196016-30","doi-asserted-by":"crossref","unstructured":"Standards of medical care in diabetes-2015: Summary of revisions. Diabetes Care 2015; 38 Suppl:S4.","DOI":"10.2337\/dc15-S003"},{"key":"key-10.4103\/2230-8210.196016-31","first-page":"1","volume-title":"RSSDI clinical practice recommendations for management of type 2 diabetes mellitus, 2015","author":"Madhu","year":"2015","journal-title":"Int J Diabetes Dev Ctries"},{"key":"key-10.4103\/2230-8210.196016-32","first-page":"250","volume-title":"Policies, guidelines and consensus statements: Pharmacologic management of type 2 diabetes-2015 interim update","author":"Canadian","year":"2015","journal-title":"Can J Diabetes"},{"key":"key-10.4103\/2230-8210.196016-33","unstructured":"International Diabetes Federation. Managing Older People with Type 2 Diabetes Global Guideline 2013. Available from: http:\/\/www.idf.org\/guidelines-older-people-type-2-diabetes. [Last accessed on 2016 Jul 15]."},{"key":"key-10.4103\/2230-8210.196016-34","unstructured":"National Institute for Health and Care Excellence. Canagliflozin, Dapagliflozin and Empagliflozin as Monotherapies for Treating Type 2 Diabetes 2016. Available from: http:\/\/www.nice.org.uk\/guidance\/ta390. [Last accessed on 2016 Jul 15]."},{"key":"key-10.4103\/2230-8210.196016-35","unstructured":"National Institute for Health and Care Excellence. Canagliflozin in Combination Therapy for Treating Type 2 Diabetes 2014. Available from: http:\/\/www.nice.org.uk\/guidance\/ta315. [Last accessed on 2016 Jul 15]."},{"key":"key-10.4103\/2230-8210.196016-36","unstructured":"INVOKANA \u00ae (Canagliflozin) Tablets. Highlights of Prescribing Information; 2016. Available from: https:\/\/www.icanimagine.com\/file-resource\/be183ed7-5830-4369-b0c0-35220e3eecdc. [Last accessed on 2016 Oct 05]."},{"key":"key-10.4103\/2230-8210.196016-37","doi-asserted-by":"crossref","unstructured":"Plosker GL. Canagliflozin: A review of its use in patients with type 2 diabetes mellitus. Drugs 2014;74:807-24.","DOI":"10.1007\/s40265-014-0225-5"},{"key":"key-10.4103\/2230-8210.196016-38","first-page":"543","volume-title":"SGLT2 inhibitors-an insulin-independent therapeutic approach for treatment of type 2 diabetes: Focus on canagliflozin","author":"Seufert","year":"2015","journal-title":"Diabetes Metab Syndr Obes"},{"key":"key-10.4103\/2230-8210.196016-39","first-page":"399","volume-title":"Canagliflozin-current status in the treatment of type 2 diabetes mellitus with focus on clinical trial data","author":"Bhatia","year":"2014","journal-title":"World J Diabetes"},{"key":"key-10.4103\/2230-8210.196016-40","first-page":"105","volume-title":"Efficacy and safety of canagliflozin in type 2 diabetes mellitus: Systematic review of randomized controlled trials","author":"Parveen","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"key-10.4103\/2230-8210.196016-41","first-page":"601","volume-title":"Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus","author":"Devineni","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"key-10.4103\/2230-8210.196016-42","first-page":"669","volume-title":"Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects","author":"Sha","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"key-10.4103\/2230-8210.196016-43","first-page":"1502","volume-title":"Sodium-glucose cotransporter-2 inhibition and the glomerulus: A review","author":"Kalra","year":"2016","journal-title":"Adv Ther"},{"key":"key-10.4103\/2230-8210.196016-44","first-page":"166","volume-title":"SGLT2 inhibitors for treatment of type 2 diabetes mellitus: Focus on canagliflozin","author":"Singh","year":"2014","journal-title":"Muller J Med Sci Res","ISSN":"https:\/\/id.crossref.org\/issn\/0975-9727","issn-type":"print"},{"key":"key-10.4103\/2230-8210.196016-45","first-page":"2154","volume-title":"Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: Results of a randomized, placebo-controlled study","author":"Polidori","year":"2013","journal-title":"Diabetes Care"},{"key":"key-10.4103\/2230-8210.196016-46","first-page":"e30555","volume-title":"Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models","author":"Liang","year":"2012","journal-title":"PLoS One"},{"key":"key-10.4103\/2230-8210.196016-47","first-page":"1296","volume-title":"Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: Results of a randomized trial","author":"Stein","year":"2014","journal-title":"Metabolism"},{"key":"key-10.4103\/2230-8210.196016-48","first-page":"279","volume-title":"Effect of food on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, and assessment of dose proportionality in healthy participants","author":"Devineni","year":"2015","journal-title":"Clin Pharmacol Drug Dev"},{"key":"key-10.4103\/2230-8210.196016-49","first-page":"129","volume-title":"Single- and multiple-dose pharmacokinetics and pharmacodynamics of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants","author":"Devineni","year":"2015","journal-title":"Int J Clin Pharmacol Ther"},{"key":"key-10.4103\/2230-8210.196016-50","doi-asserted-by":"crossref","unstructured":"Devineni D, Polidori D, Curtin C, Stieltjes H, Tian H, Wajs E. Single-dose pharmacokinetics and pharmacodynamics of canagliflozin, a selective inhibitor of sodium glucose cotransporter 2, in healthy Indian participants. Clin Ther 2016;38:89-98.e1.","DOI":"10.1016\/j.clinthera.2015.11.008"},{"key":"key-10.4103\/2230-8210.196016-51","doi-asserted-by":"crossref","unstructured":"Devineni D, Murphy J, Wang SS, Stieltjes H, Rothenberg P, Scheers E, et al. Absolute oral bioavailability and pharmacokinetics of canagliflozin: A microdose study in healthy participants. Clin Pharmacol Drug Dev 2015;4:295-304.","DOI":"10.1002\/cpdd.162"},{"key":"key-10.4103\/2230-8210.196016-52","first-page":"1027","volume-title":"Clinical pharmacokinetic, pharmacodynamic, and drug-drug interaction profile of canagliflozin, a sodium-glucose co-transporter 2 inhibitor","author":"Devineni","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"key-10.4103\/2230-8210.196016-53","first-page":"226","volume-title":"Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participants","author":"Devineni","year":"2015","journal-title":"Clin Pharmacol Drug Dev"},{"key":"key-10.4103\/2230-8210.196016-54","unstructured":"FARXIGA \u00ae (Dapagliflozin) Tablets. Highlights of Prescribing Information; 2014. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/202293s003lbl.pdf. [Last accessed on 2016 Oct 05]."},{"key":"key-10.4103\/2230-8210.196016-55","unstructured":"JARDIANCE \u00ae (Empagliflozin) Tablets. Highlights of Prescribing Information; 2014. Available from: http:\/\/docs.boehringer-ingelheim.com\/Prescribing%20Information\/PIs\/Jardiance\/jardiance.pdf. [Last accessed on 2016 Oct 05]."},{"key":"key-10.4103\/2230-8210.196016-56","first-page":"e143","volume-title":"Efficacy, safety and regulatory status of SGLT2 inhibitors: Focus on canagliflozin","author":"Haas","year":"2014","journal-title":"Nutr Diabetes"},{"key":"key-10.4103\/2230-8210.196016-57","unstructured":"European Medicines Agency. Invokana 100 and 300 mg Filmcoated Tablets: Summary of Product Characteristics; 2013. Accessed from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002649\/WC500156456.pdf. [Last accessed on 2016 Jul 15]."},{"key":"key-10.4103\/2230-8210.196016-58","unstructured":"Central Drugs Standard Control Organization. List of FDC and new drugs approved for marketing in India. Available from: http:\/\/www.cdsco.nic.in\/forms\/list.aspx?lid=2056 and Id=11. [Last accessed on 2016 Jul 15]."},{"key":"key-10.4103\/2230-8210.196016-59","first-page":"372","volume-title":"Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise","author":"Stenl\u00f6f","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"key-10.4103\/2230-8210.196016-60","first-page":"163","volume-title":"Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: Findings from the 52-week CANTATA-M study","author":"Stenl\u00f6f","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"key-10.4103\/2230-8210.196016-61","first-page":"1325","volume-title":"Efficacy and tolerability of canagliflozin as add-on to metformin in the treatment of type 2 diabetes mellitus: A meta-analysis","author":"Yang","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"key-10.4103\/2230-8210.196016-62","first-page":"e004619","volume-title":"The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: Meta-analysis of randomised controlled trials","author":"Sun","year":"2014","journal-title":"BMJ Open"},{"key":"key-10.4103\/2230-8210.196016-63","first-page":"2582","volume-title":"Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: A randomised trial","author":"Lavalle-Gonz\u00e1lez","year":"2013","journal-title":"Diabetologia"},{"key":"key-10.4103\/2230-8210.196016-64","first-page":"2508","volume-title":"Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: A 52-week randomized trial","author":"Schernthaner","year":"2013","journal-title":"Diabetes Care"},{"key":"key-10.4103\/2230-8210.196016-65","first-page":"941","volume-title":"Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial","author":"Cefalu","year":"2013","journal-title":"Lancet"},{"key":"key-10.4103\/2230-8210.196016-66","doi-asserted-by":"crossref","unstructured":"Leiter LA, Yoon KH, Arias P, Langslet G, Xie J, Balis DA, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: A randomized, double-blind, phase 3 study. Diabetes Care 2015;38:355-64.","DOI":"10.2337\/dc13-2762"},{"key":"key-10.4103\/2230-8210.196016-67","first-page":"467","volume-title":"Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone","author":"Forst","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"key-10.4103\/2230-8210.196016-68","first-page":"1267","volume-title":"Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: A randomised trial","author":"Wilding","year":"2013","journal-title":"Int J Clin Pract"},{"key":"key-10.4103\/2230-8210.196016-69","first-page":"539","volume-title":"Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin","author":"Devineni","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"key-10.4103\/2230-8210.196016-70","first-page":"403","volume-title":"Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes","author":"Neal","year":"2015","journal-title":"Diabetes Care"},{"key":"key-10.4103\/2230-8210.196016-71","first-page":"812","volume-title":"Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin","author":"Rodbard","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"key-10.4103\/2230-8210.196016-72","first-page":"82","volume-title":"Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes","author":"Fulcher","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"key-10.4103\/2230-8210.196016-73","first-page":"S260","volume-title":"PO422 efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from India","author":"Kumar","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"key-10.4103\/2230-8210.196016-74","first-page":"372","volume-title":"Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from India","author":"Prasanna","year":"2016","journal-title":"Indian J Endocrinol Metab"},{"key":"key-10.4103\/2230-8210.196016-75","first-page":"1136","volume-title":"Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, 12-week study","author":"Inagaki","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"key-10.4103\/2230-8210.196016-76","first-page":"72","volume-title":"Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: A randomized trial","author":"Bode","year":"2013","journal-title":"Hosp Pract"},{"key":"key-10.4103\/2230-8210.196016-77","first-page":"294","volume-title":"Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes","author":"Bode","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"key-10.4103\/2230-8210.196016-78","first-page":"438","volume-title":"Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus","author":"Wilding","year":"2015","journal-title":"J Diabetes Complications"},{"key":"key-10.4103\/2230-8210.196016-79","first-page":"A609","volume-title":"Bayesian network meta-analysis to assess the relative efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin","author":"Pacou","year":"2013","journal-title":"Value Health"},{"key":"key-10.4103\/2230-8210.196016-80","doi-asserted-by":"crossref","unstructured":"Schroeder M, Taieb V, Pacou M, Ho S, Nielsen AT, Schubert A, et al. A Network meta-analysis to assess options for treatment intensification for patients with type 2 diabetes inadequately controlled on dual therapy. Poster presented at the 51st annual meeting of the European Association for the Study of Diabetes (EASD); 14-18 September, Stockholm, Sweden; 2015.","DOI":"10.1016\/j.jval.2015.09.2046"},{"key":"key-10.4103\/2230-8210.196016-81","first-page":"A431","volume-title":"Bayesian network meta-analysis to assess the relative efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin and sulphonylurea (MET+SU)","author":"Pacou","year":"2013","journal-title":"Value Health"},{"key":"key-10.4103\/2230-8210.196016-82","doi-asserted-by":"crossref","unstructured":"Taieb V, Pacou M, Schroeder M, Nielsen AT, Schubert A, Neslusan C. A Network meta-analysis (NMA) to assess the longer-term relative efficacy of canagliflozin in patients with type 2 diabetes inadequately controlled on metformin. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual European Congress; 7-11 November, Milan, Italy; 2015.","DOI":"10.1016\/j.jval.2015.09.2046"},{"key":"key-10.4103\/2230-8210.196016-83","first-page":"A54","volume-title":"Bayesian network meta-analysis (NMA) to assess relative efficacy of canagliflozin (CANA) versus glucagon-like peptide-1 (GLP-1) agonists in dual and triple therapy in patients with type 2 diabetes mellitus (T2DM)","author":"van","year":"2015","journal-title":"Value Health"},{"key":"key-10.4103\/2230-8210.196016-84","doi-asserted-by":"crossref","unstructured":"Bays HE, Weinstein R, Law G, Canovatchel W. Canagliflozin: Effects in overweight and obese subjects without diabetes mellitus. Obesity (Silver Spring) 2014;22:1042-9.","DOI":"10.1002\/oby.20663"},{"key":"key-10.4103\/2230-8210.196016-85","first-page":"875","volume-title":"Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus","author":"Weir","year":"2014","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"key-10.4103\/2230-8210.196016-86","doi-asserted-by":"crossref","unstructured":"Seufert J. SGLT-2 inhibition with canagliflozin: A new option for the treatment of type 2 diabetes. Dtsch Med Wochenschr 2014;139 Suppl 2:S52-8.","DOI":"10.1055\/s-0033-1359991"},{"key":"key-10.4103\/2230-8210.196016-87","doi-asserted-by":"crossref","unstructured":"Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis. J Am Soc Hypertens 2014;8:262-75.e9.","DOI":"10.1016\/j.jash.2014.01.007"},{"key":"key-10.4103\/2230-8210.196016-88","first-page":"854","volume-title":"Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes","author":"Mikhail","year":"2014","journal-title":"World J Diabetes"},{"key":"key-10.4103\/2230-8210.196016-89","unstructured":"Summary of Product Characteristics of INVOKANA. UK: Janssen-Cilag Ltd.; 2015. Available from: https:\/\/www.medicines.org.uk\/emc\/medicine\/28401. [Last accessed on 2016 Jul 15]."},{"key":"key-10.4103\/2230-8210.196016-90","doi-asserted-by":"crossref","unstructured":"Neal B, Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Stein P, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS) \u2013 a randomized placebo-controlled trial. Am Heart J 2013;166:217-23.e11.","DOI":"10.1016\/j.ahj.2013.05.007"},{"key":"key-10.4103\/2230-8210.196016-91","unstructured":"CANVAS-R. Available from: http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01989754?term=canvas-r and rank=1. [Last accessed on 2016 Jul 15]."},{"key":"key-10.4103\/2230-8210.196016-92","first-page":"16","volume-title":"Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: Pooled analysis of phase 3 study results","author":"Usiskin","year":"2014","journal-title":"Postgrad Med"},{"key":"key-10.4103\/2230-8210.196016-93","first-page":"A1178","volume-title":"Incidence of genital mycotic infections decreases over time in patients with type 2 diabetes mellitus treated with canagliflozin over 2 years","author":"Sobel","year":"2015","journal-title":"Diabetes"},{"key":"key-10.4103\/2230-8210.196016-94","unstructured":"Goldenberg RM, Sobel JD, Khunti K, Davies MJ, Vijapurkar U, Meininger G. Incidence of genital mycotic infections and urinary tract infections in patients with type 2 diabetes mellitus treated with canagliflozin over 2 years. Poster presented at the 23rd World Diabetes Congress of the International Diabetes Federation (IDF); 30 November-4 December, Vancouver, BC, Canada; 2015."},{"key":"key-10.4103\/2230-8210.196016-95","first-page":"37","volume-title":"Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: A pooled analysis of clinical studies","author":"Sinclair","year":"2014","journal-title":"BMC Endocr Disord"},{"key":"key-10.4103\/2230-8210.196016-96","first-page":"7","volume-title":"Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor","author":"Nicolle","year":"2014","journal-title":"Postgrad Med"},{"key":"key-10.4103\/2230-8210.196016-97","unstructured":"Janssen Research and Development LLC. Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants with Diabetic Nephropathy (CREDENCE). US National Institutes of Health; 2014. Available from: http:\/\/www.clinicaltrials.gov\/ct2\/show\/study\/NCT02065791. [Last accessed on 2016 Jul 15]."},{"key":"key-10.4103\/2230-8210.196016-98","unstructured":"U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA Warns that SGLT2 Inhibitors for Diabetes May Result in a Serious Condition of Too Much Acid in the Blood. Available from: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm446845.htm. [Last accessed on 2016 Jul 15]."},{"key":"key-10.4103\/2230-8210.196016-99","first-page":"21","volume-title":"Euglycemic ketoacidosis and sodium glucose co-transporter 2 inhibitors: Is this novel class safe for the diabetic patients?","author":"Soni","year":"2015","journal-title":"MOJ Toxicol"},{"key":"key-10.4103\/2230-8210.196016-100","first-page":"524","volume-title":"Sodium glucose transporter 2 (SGLT2) inhibition and ketogenesis","author":"Kalra","year":"2015","journal-title":"Indian J Endocrinol Metab"},{"key":"key-10.4103\/2230-8210.196016-101","first-page":"1680","volume-title":"Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program","author":"Erondu","year":"2015","journal-title":"Diabetes Care"},{"key":"key-10.4103\/2230-8210.196016-102","first-page":"753","volume-title":"American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis","author":"Handelsman","year":"2016","journal-title":"Endocr Pract"},{"key":"key-10.4103\/2230-8210.196016-103","first-page":"157","volume-title":"Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus","author":"Watts","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"key-10.4103\/2230-8210.196016-104","unstructured":"Food and Drug Administration. FDA Drug Safety Communication: Interim Clinical Trial Results Find Increased Risk of Leg and Foot Amputations, Mostly Affecting the Toes, with the Diabetes Medicine Canagliflozin (Invokana, Invokamet); FDA to Investigate. Available from: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm500965.htm. [Last accessed on 2016 Jul 15]."},{"key":"key-10.4103\/2230-8210.196016-105","unstructured":"Drug Safety Alert for Canagliflozin. Available from: http:\/\/www.scpod.org\/news\/drug-safety-alert-for-canagliflozin\/. [Last accessed on 2016 Jul 15]."},{"key":"key-10.4103\/2230-8210.196016-106","first-page":"332","volume-title":"Liraglutide vs.exenatide: Patient adherence, medication persistence and economic evaluation in the treatment of type 2 diabetes mellitus","author":"Santoleri","year":"2014","journal-title":"Pharmacol Pharm"},{"key":"key-10.4103\/2230-8210.196016-107","unstructured":"Jain R, Cai J, Fu AC, Chow W, Tan H. Real world (RW) glycemic control and medication adherence among patients with type 2 diabetes mellitus (T2DM) initiated on canagliflozin. Poster Presentation. American Diabetes Association, 76th scientific sessions, New Orleans, Louisiana; 2016. p. 1161."},{"key":"key-10.4103\/2230-8210.196016-108","first-page":"CR72","volume-title":"Persistence of initial oral antidiabetic treatment in patients with type 2 diabetes mellitus","author":"Jermendy","year":"2012","journal-title":"Med Sci Monit"},{"key":"key-10.4103\/2230-8210.196016-109","first-page":"491","volume-title":"Persistence patterns with oral hypoglycemic agents in type 2 diabetes","author":"Stephens","year":"2002","journal-title":"JCOM"},{"key":"key-10.4103\/2230-8210.196016-110","first-page":"A68","volume-title":"Comparative persistency with newer agents used to treat type 2 diabetes (T2DM) in the United States: Canagliflozin versus dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) agonists","author":"Diels","year":"2015","journal-title":"Value Health"},{"key":"key-10.4103\/2230-8210.196016-111","unstructured":"Cai J, Wang Y, Baser O, Xie L, Diels J, Neslusan C, et al. Comparative persistence with antihyperglycemic agents (AHA) used to treat type 2 diabetes mellitus (T2DM) in the real world. Poster Presentation. American Diabetes Association, 76th scientific sessions, New Orleans, Louisiana; 2016. p. 1155."},{"key":"key-10.4103\/2230-8210.196016-112","first-page":"341","volume-title":"Impact of medication adherence and persistence on clinical and economic outcomes in patients with type 2 diabetes treated with liraglutide: A retrospective cohort study","author":"Buysman","year":"2015","journal-title":"Adv Ther"},{"key":"key-10.4103\/2230-8210.196016-113","first-page":"A359","volume-title":"Non-adherence and non-persistence related to Glp-1 therapy in patients with diabetes mellitus type 2 (T2dm): Analysis of a large german claims-based dataset and comparison to oral anti-diabetics","author":"Wilke","year":"2014","journal-title":"Value Health"},{"key":"key-10.4103\/2230-8210.196016-114","doi-asserted-by":"crossref","unstructured":"Foley JE, Jordan J. Weight neutrality with the DPP-4 inhibitor, vildagliptin: Mechanistic basis and clinical experience. Vasc Health Risk Manag 2010;6:541-8.","DOI":"10.2147\/VHRM.S10952"},{"key":"key-10.4103\/2230-8210.196016-115","first-page":"S5","volume-title":"Distinguishing among incretin-based therapies.Pathophysiology of type 2 diabetes mellitus: Potential role of incretin-based therapies","author":"Campbell","year":"2010","journal-title":"J Fam Pract"},{"key":"key-10.4103\/2230-8210.196016-116","first-page":"137","volume-title":"Characteristics and short-term outcomes of patients with type 2 diabetes mellitus treated with canagliflozin in a real-world setting","author":"Buysman","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"key-10.4103\/2230-8210.196016-117","first-page":"A55","volume-title":"PDB16.Real-world treatment patterns of antihyperglycemic agents among patients with type 2 diabetes mellitus (T2DM) initiated on canagliflozin","author":"Chow","year":"2015","journal-title":"Value Health"},{"key":"key-10.4103\/2230-8210.196016-118","first-page":"A57","volume-title":"Glycated hemoglobin (HbA1c) control in patients with type 2 diabetes mellitus (T2DM) treated with canagliflozin in a real-world setting","author":"Lefebvre","year":"2015","journal-title":"Value Health"},{"key":"key-10.4103\/2230-8210.196016-119","first-page":"A54","volume-title":"Real-world canagliflozin utilization: Impact on glycemic control in patients with type 2 diabetes mellitus","author":"Meckley","year":"2015","journal-title":"Value Health"},{"key":"key-10.4103\/2230-8210.196016-120","first-page":"32:1087","volume-title":"Real-world evaluation of glycemic control among patients with type 2 diabetes mellitus treated with canagliflozin versus dipeptidyl peptidase-4 inhibitors","author":"Thayer","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"key-10.4103\/2230-8210.196016-121","first-page":"A345","volume-title":"The cost-effectiveness of canagliflozin verse liraglutide in patients with type 2 diabetes (T2dm) failing to achieve glycaemic control on metformin monotherapy in Ireland","author":"Bacon","year":"2014","journal-title":"Value Health"},{"key":"key-10.4103\/2230-8210.196016-122","first-page":"A346","volume-title":"The Cost-effectiveness of canagliflozin compared with liraglutide in patients with type 2 diabetes inadequately controlled with metformin and sulfonylurea in France","author":"Troelsgaard","year":"2014","journal-title":"Value Health"},{"key":"key-10.4103\/2230-8210.196016-123","first-page":"8","volume-title":"Cost-effectiveness of canagliflozin versus sitagliptin as add-on to metformin in patients with type 2 diabetes mellitus in Mexico","author":"Neslusan","year":"2015","journal-title":"Value Health Reg Issues"}],"container-title":["Indian Journal of Endocrinology and Metabolism"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:24:01Z","timestamp":1786713841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/2230-8210.196016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":123,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017]]}},"alternative-id":["196016"],"URL":"https:\/\/doi.org\/10.4103\/2230-8210.196016","relation":{},"ISSN":["2230-8210"],"issn-type":[{"value":"2230-8210","type":"print"}],"subject":[],"published":{"date-parts":[[2017]]}}}